Investorideas.com Newswire

Investorideas.com Newswire
Be one of the most talked about companies (stocks) on social media

Thursday, October 18, 2018

Investorideas.com - #HealthcareStock News: China Infrastructure Construction Corp. (OTCPK: $CHNC) and America's Advanced Wellness Centers, LLC (AAWC) Enter Into Acquisition Agreement

Investorideas.com - #HealthcareStock News: China Infrastructure Construction Corp. (OTCPK: $CHNC) and America's Advanced Wellness Centers, LLC (AAWC) Enter Into Acquisition Agreement



#HealthcareStock News: China Infrastructure Construction Corp. (OTCPK: $CHNC) and America's Advanced Wellness Centers, LLC (AAWC) Enter Into Acquisition Agreement


HOUSTON, TX - October 18, 2018 (Investorideas.com Newswire) China Infrastructure Construction Corp. (OTC: CHNC) www.thechnc.com is pleased to announce the acquisition of America's Advanced Wellness Centers, LLC (AAWC). AAWC is a five-part medical clinic/clinical research company consisting of Family Medicine, Obstetrics-Gynecology, Medical Weight Loss, a Wholesale/Direct-Mail Pharmacy, and a Clinical Research Center. AAWC brings multi-million dollar contracts with the biggest pharmaceutical companies in the world, like Pfizer and Allergan, to name a few. President & CEO Elizabeth Hernandez says, "Aside from being at the forefront of finding cures and treatments for disease, the acquisition of AAWC's clinical research arm allows CHNC to have another revenue-generating model that will allow some its members to receive medical care at little or no cost. We expect more acquisitions like that of AAWC in the future as clinics/doctors see the quality of care CHNC provides its members and the quality of life its doctors are experiencing as a result of using CHNC's model of care. We are always looking to build shareholder value and this acquisition does just that."
The acquisition, which has been approved by the board of directors, is subject to certain closing conditions, including OTC approval, approval by stockholders of China Infrastructure Construction Corp. (CHNC), minimum cash balance of CHNC at closing, and other customary closing conditions.
About China Infrastructure Construction Corp. (CHNC)
China Infrastructure Construction Corp. (CHNC), through its wholly-owned subsidiary Hippocrates Direct Healthcare, Inc., is innovating healthcare by redefining the doctor-patient relationship. Direct access to physicians, by its clients, is the cornerstone of Hippocrates. It is understandable why patients and providers are both dissatisfied with the way medical care is delivered. From a patient's perspective, medical care is a vast web of bureaucracy that is expensive, time consuming, and lacking in considerations for patient care and comfort. The care provided is minimal, five to ten minutes per visit at best, and one to two problems per visit as well. As a result, quality of care and results are sorely lacking—this is the TRUE cause of the crisis we face in medical care today. Hippocrates Direct will correct this problem. Hippocrates Direct offers concierge medicine through its membership-based model. The company will own and staff individual clinical facilities initially in the Houston Metro area and will expand nationwide. More information can be found online at www.thechnc.com
Hippocrates Direct Healthcare, Inc. is a wholly-owned subsidiary of China Infrastructure (CHNC). China Infrastructure's common stock trades on the OTC Markets under the ticker symbol "CHNC."
Safe Harbor Statement
The information posted in this release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by use of the words "may," "will," "should," "plans," "explores," "expects," "anticipates," "continue," "estimate," "projects," "intends," and similar phrases. Forward-looking statements involve risks and uncertainties that could cause actual results to differ from those projected or anticipated. These risks and uncertainties include, but are not limited to, general economic and business conditions, effects of geopolitical conditions, competition, changes in technology and methods of marketing, and various other factors beyond the company's control.
Hippocrates Direct Healthcare™ and the Hippocrates Direct Healthcare™ logo are all trademarks or registered trademarks of Hippocrates Direct Healthcare™, Inc.
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ Disclosure this is a paid for news release
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: https://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.
Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

BiotechIndustryStocks.com - A Leading Global Investor Website for Biotech Industry Stocks

BiotechIndustryStocks.com - investing ideas in biotechnology stocks, medical technology and life sciences

Like Biotech Stocks? View our Biotech Stocks Directory

Get News Alerts on Biotech Stocks

Friday, October 12, 2018

Investorideas.com - Investor Ideas adds Nasdaq #Biotech #IPOs and CSE #Mining IPO Stocks to Directories (NASDAQ: $ADIL), (NASDAQ: $ALLK) (NASDAQ: $AQST), (CSE: $ZX.C)

Investorideas.com - Investor Ideas adds Nasdaq #Biotech #IPOs and CSE #Mining IPO Stocks to Directories (NASDAQ: $ADIL), (NASDAQ: $ALLK) (NASDAQ: $AQST), (CSE: $ZX.C)



Join our smart investors - Get the best stock directories in  blockchain, cannabis, crypto, AI, IoT, cleantech. Daily podcasts in cannabis and crpto. Just $99  a year




Investor Ideas adds Nasdaq #Biotech #IPOs and CSE #Mining IPO Stocks to Directories (NASDAQ: $ADIL), (NASDAQ: $ALLK) (NASDAQ: $AQST), (CSE: $ZX.C)


Point Roberts, WA and Delta, BC - September 21, 2018 (Investorideas.com Newswire) Investorideas.com, a global news source and leading investor resource announces this week's additions to its global stock directories in biotech and mining.
Investorideas.com is a go- to destination for retail investors and tracks companies in high-profile trading sectors and makes ongoing additions to its stock directories for its followers and members . (https://www.investorideas.com/membership/)
The newest companies in biotech are all Nasdaq IPO listings from within the past few weeks and include pharmaceutical, medical device and biopharma companies looking to treat a variety of diseases and unmet medical conditions/needs.
The latest mining company is a recent CSE listing that is exploring and developing properties in Quebec and BC, Canada.
New Biotech Companies
ADIAL PHARMACEUTICALS, INC. (NasdaqCM: ADIL) is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions. The Company's lead investigational new drug candidate, AD04, is a genetically targeted therapeutic agent for the treatment of alcohol use disorder (AUD). A Phase 2b clinical trial of AD04 for the treatment of AUD showed promising results in reducing frequency of drinking, quantity of drinking and heavy drinking (all with statistical significance), and no overt safety concerns (there were no statistically significant serious adverse events reported). The Company plans to commence a Phase 3 clinical trial using AD04 for the potential treatment of AUD in subjects with certain target genotypes, which are to be identified using the Company's proprietary companion diagnostic genetic test. AD04 is also believed to have the potential to treat other addictive disorders such as opioid use disorder, gambling, and obesity.
ALLAKOS INC. (NasdaqGS:ALLK) is a clinical stage company developing antibodies that target immunomodulatory receptors present on immune effector cells involved in allergic, inflammatory, and proliferative diseases. The Company's lead antibody, AK002, targets Siglec-8, an inhibitory receptor selectively expressed on human mast cells and eosinophils. Inappropriately activated eosinophils and mast cells have been identified as key drivers in a number of severe diseases affecting the gastrointestinal tract, eyes, skin, lungs and other organs. AK002 has completed two Phase 1 trials, one in healthy volunteers and a single ascending dose trial in patients with indolent systemic mastocytosis. AK002 demonstrated pharmacodynamic activity in both trials and in the trial involving patients with indolent systemic mastocytosis, patients reported improvements in their symptoms. AK002 is being tested in a Phase 2 trial for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis. In addition, Allakos is conducting multiple-dose trials with AK002 in chronic urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis.
AQUESTIVE THERAPEUTICS, INC. (NasdaqGM: AQST) is a specialty pharmaceutical company focused on identifying, developing and commercializing differentiated products to address unmet medical needs. Aquestive Therapeutics has a late-stage proprietary product pipeline focused on the treatment of CNS diseases, and is working to advance orally-administered complex molecules that it believes can be alternatives to invasively-administered standard of care therapies. As the leader in developing and delivering drugs via its PharmFilm® technology, Aquestive Therapeutics also collaborates with pharmaceutical partners to bring new molecules to market in differentiated and highly-marketable dosage forms.
CONSTELLATION PHARMACEUTICALS INC (NasdaqGS:CNST) is a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance.  With a decade of experience in the field, the Company has a deep understanding of how epigenetic regulators modulate gene expression in cancer cells and in the tumor and immune microenvironment.  Constellation is translating these insights to advance the Company's two lead clinical programs, the EZH2 inhibitor CPI-1205 for metastatic castration-resistant prostate cancer and solid tumors and the BET inhibitor CPI-0610 for myelofibrosis, and to explore other novel targets for which cancer epigenetics may enhance outcomes over currently available treatment options.
CRINETICS PHARMACEUTICALS, INC. (NasdaqGS:CRNX) is a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly, an orphan disease affecting more than 25,000 people in the United States. The company is also developing other oral nonpeptide somatostatin agonists for hyperinsulinism and neuroendocrine tumors, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. Crinetics was founded by a team of scientists with a track record of endocrine drug discovery and development.
ESTABLISHMENT LABS HOLDINGS INC. (NasdaqCM:ESTA) is a global medical technology company focused on improving patient safety and aesthetic outcomes, initially in the breast aesthetics and reconstruction market, by designing, developing, manufacturing and marketing an innovative portfolio of silicone gel-filled breast implants, branded as Motiva Implants®, the centerpiece of the MotivaImagine® platform. Motiva Implants® are produced at two FDA compliant state-of-the-art facilities in Costa Rica and currently sold in over 60 countries through exclusive distributors or the Company's direct salesforce. In March 2018, Establishment Labs received approval for an investigational device exemption (IDE) from the FDA and initiated the Motiva Implant® clinical trial in the United States in April 2018. In addition to Motiva Implants®, Establishment Labs' product and technologies portfolio includes the Divina® 3D Simulation System, Puregraft and MotivaImage® Centers.
LIQUIDIA TECHNOLOGIES INC (NasdaqCM: LQDA) is a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the lives of patients. PRINT® is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. Currently, Liquidia is focused on the development of two product candidates for which it holds worldwide commercial rights: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Liquidia's lead product candidate, LIQ861, currently being evaluated in a Phase 3 clinical trial (INSPIRE), is designed to improve the therapeutic profile of treprostinil by enhancing deep-lung delivery and achieving higher dose levels than current inhaled therapies by using a convenient, disposable dry powder inhaler. LIQ865, for which Liquidia has recently completed a U.S. Phase 1b clinical trial, is designed to deliver sustained-release particles of bupivacaine, a non-opioid anesthetic, to treat local post-operative pain for three to five days through a single administration. In addition to developing its own product candidates, Liquidia collaborates with leading pharmaceutical companies to develop their own product candidates across a wide range of therapeutic areas, molecule types and routes of administration, leveraging Liquidia's PRINT® technology.
PROVENTION BIO, INC (NasdaqCM:PRVB) is a clinical-stage biopharmaceutical company leveraging a transformational drug development strategy that is focused on the prevention or interception of immune-mediated disease. Our diverse portfolio was assembled with product candidates that have undergone clinical testing but may have been underdeveloped or deprioritized assets at other companies. Provention's mission is to in-license, transform and develop clinical-stage, or nearly clinical-stage, therapeutic candidates targeting the high morbidity, mortality and escalating costs of autoimmune and inflammatory diseases including: type 1 diabetes (T1D), Crohn's disease, ulcerative colitis, lupus, and certain life-threating viral diseases.
REPLIMUNE GROUP, INC. (NasdaqGS:REPL) headquartered in Woburn, MA, was founded in 2015 to develop the next generation of "oncolytic immunotherapies" for the treatment of cancer. Replimune is developing novel, proprietary therapeutics intended to improve the direct cancer-killing effects of selective virus replication and the potency of the immune response to the tumor antigens released. The Company's Immulytic™ platform is designed to maximize systemic immune activation, in particular to tumor neoantigens, through robust viral mediated immunogenic tumor cell killing and the delivery of optimal combinations of immune-activating proteins to the tumor and draining lymph nodes. The approach is expected to be highly synergistic with immune checkpoint blockade and other approaches to cancer treatment. Replimune intends to progress these therapies rapidly through clinical development in combination with other immuno-oncology products with complementary mechanisms of action
RUBIUS THERAPEUTICS, INC. (NasdaqGS:RUBY) is a biopharmaceutical company pioneering the development of a new class of medicines called Red Cell Therapeutics™. The Company's proprietary RED PLATFORM™ was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and ready-to-use cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Rubius' initial focus is to advance RCT™ product candidates for the treatment of rare diseases, cancer and autoimmune diseases by leveraging three distinct therapeutic modalities — cellular shielding, potent cell-cell interaction and tolerance induction
VACCINEX, INC. (NasdqGM: VCNX) is a clinical-stage immunotherapy company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders, with currently active clinical trials in Non-Small Cell Lung Cancer and Huntington's disease. Vaccinex is based in Rochester, New York.
New Mining Companies
Zenith Exploration Inc. (CSE:ZX) is a resource exploration issuer that acquires and explores mineral properties. Zenith's principal property is in Quebec and its secondary property is in BC. The Company intends to explore and develop these properties.
The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news source publishing third party news and press releases plus we create original financial content. Learn about investing in stocks and  sector trends  from Investorideas.com with our news alerts , articles , podcasts and videos  talking about cannabis,  crypto,  technology including  AI and IoT , mining ,sports biotech, water, renewable energy and more . Investorideas.com original branded content includes the daily Crypto Corner and Podcast, Play by Play sports and stock news column, Investor Ideas #Potcasts#Cannabis News and Stocks on the Move podcast and column,  Cleantech and Climate Change Podcast. 
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer and disclosure info: https://www.investorideas.com/About/Disclaimer.asp.
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: https://www.bcsc.bc.ca/release.aspx?id=6894.  Global investors must adhere to regulations of each country.
Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Learn more about our news, PR and social media services at Investorideas.com
Follow us on Twitter https://twitter.com/Investorideas
To sponsor one of our podcasts or columns or be a guest call us today!
Contact Investorideas.com
800-665-0411

Friday, August 31, 2018

Investorideas.com - #Cannabis, #Biotech, #China and #Mining #Stocks added to Investor Ideas

Investorideas.com - #Cannabis, #Biotech, #China and #Mining #Stocks added to Investor Ideas





#Cannabis, #Biotech, #China
and #Mining #Stocks added to Investor Ideas

Point Roberts, WA, Delta BC – August 31, 2018 –
(Investorideas.com Newswire) Investorideas.com, a global news source and
leading investor resource covering actively traded sectors announces this
week’s additions to its
global stock
directories
in cannabis, biotech, China-Asia and mining.

Investorideas.com tracks companies in high-profile
trading sectors and makes ongoing additions to its stock directories for its
members.  Free previews of all
directories are available to the public with full login access only accessible
to members.


The newest cannabis companies are involved in
hemp-based CBD products and medical cannabis respectively.

The latest biotech companies include a medical
device company, a gene therapy company and a pharma company involved in
developing anti-infectives.

New China-Asia companies are involved in the
education and IT-Fintech sectors.  The
newest mining company is working in Mexico at the
Rebeico Gold-Copper project.

New Cannabis Companies:
Charlotte's Web Holdings, Inc. (CSE: CWEB) is a market
leader in the production and distribution of innovative hemp-based, CBD
wellness products. Through its vertically integrated business model,
CWEB strives to improve customers’ lives and meet their demands for
stringent product quality, efficacy and consistency.

Pure Global Cannabis Inc. (TSX:PURE.V; OTC: PRCNF) is a vertically-integrated, growth-oriented life sciences
cannabis company led by experienced pharma-industry, horticultural, consumer
packaged goods (CPG), and supply chain experts. The Company's wholly owned
subsidiary, PureSinse Inc., is a licensed producer under the Access to Cannabis
for Medical Purposes Regulations (ACMPR) focused on producing cannabis products
for medical, wellness, health & beauty, natural health, and future legal
adult use markets.

Investorideas.com
cannabis/marijuana and hemp news and investing content now includes our daily potcastsCM ; podcasts featuring cannabis news and stocks to watch plus
insight from thought leaders and experts.
Recent
interviews include Montel Williams, The Arcview Group, Electrum Partners and
the CEO of Cronos Group Inc. (
NASDAQ: CRON).


The cannabis stocks potcast (podcast)
is also released with an accompanying written transcript.
Learn more and sign up at http://www.investorideas.com/Audio/Potcasts.aspOr www.potcasts.ca

To sponsor our daily podcast for the month or to be an expert guest
please contact us!


New Biotech Companies
Hancock
Jaffe Laboratories, Inc
. (NasdaqCM:HJLI) specializes in developing and manufacturing bioprosthetic medical
devices that establish improved standards of care for treating cardiac and
vascular diseases. HJLI currently has three product candidates: the porcine
tissue based VenoValve®, which is intended to be surgically implanted in the
deep venous system of the leg to treat Chronic Venue Insufficiency; the
CoreoGraft®, a bovine tissue based off the shelf conduit intended to be used
for coronary artery bypass surgery, and a porcine tissue based heart valve,
which based upon its relatively small size and increased output, is an ideal
candidate for pediatric aortic/mitral valve replacement.

Iterum
Therapeutics plc
(NasdaqGM:ITRM) is a clinical-stage pharmaceutical company
dedicated to developing differentiated anti-infectives aimed at combatting the
global crisis of multi-drug resistant pathogens to significantly improve the
lives of people affected by serious and life-threatening diseases around the
world. Iterum Therapeutics is advancing its first compound, sulopenem, a novel
penem anti-infective compound with oral and IV formulations that has
demonstrated potent in vitro activity against a wide variety of gram-negative,
gram-positive and anaerobic bacteria resistant to other antibiotics. Iterum
Therapeutics has received QIDP designations for its oral and IV formulations
for the treatment of uUTI, complicated urinary tract infection and complicated
intra-abdominal infection.

MeiraGTx
Holdings plc
(NasdaqGS:MGTX) is a vertically integrated, clinical stage gene
therapy company with four ongoing clinical programs and a broad pipeline of
preclinical and research programs. MeiraGTx has core capabilities in viral
vector design and optimization and gene therapy manufacturing, as well as a
potentially transformative gene regulation technology. Led by an experienced
management team, MeiraGTx has taken a portfolio approach by licensing, acquiring
and developing technologies that give depth across both product candidates and
indications. MeiraGTx’s initial focus is on three distinct areas of unmet
medical need: inherited retinal diseases, severe forms of xerostomia and
neurodegenerative diseases. Though initially focusing on the eye, salivary
gland and central nervous system, MeiraGTx intends to expand its focus in the
future to develop additional gene therapy treatments for patients suffering
from a range of serious diseases.

New China-Asia Companies
Ambow Education Holding Ltd. (NYSE:AMBO) is a leading national provider of educational and
career enhancement services in China, offering high-quality, individualized
services and products. With its extensive network of regional service hubs
complemented by a dynamic proprietary learning platform and distributors, Ambow
provides its services and products to students in 30 out of the 31 provinces
and autonomous regions within China.

CLPS Incorporation (NasdaqCM: CLPS)
is a global leading information technology ("IT"), consulting and
solutions service provider focusing on the banking, insurance and financial
sectors. The Company serves as an IT solutions provider to a growing network of
clients in the global financial industry, including large financial institutions
in the US, Europe, Australia and Hong Kong and their PRC-based IT centers. The
Company maintains eleven delivery and/or research & development centers to
serve different customers in various geographic locations. Mainland China
centers are located in Shanghai, Beijing, Dalian, Tianjin, Chengdu, Guangzhou
and Shenzhen. The remaining four global centers are located in Hong Kong,
Taiwan, Singapore and Australia.

New Mining Companies
Ridgestone
Mining Inc. (
TSX:RMI.V) is a TSX Venture Exchange -listed junior mineral
exploration company with offices in Taipei and Vancouver, B.C. The Company's
focus is on precious metals and copper in Sonora, Mexico, and specifically the
Rebeico Gold-Copper project.

The directories are not meant as recommendations
but as a research tool to discover opportunities and trading ideas in a
particular sector.

Membership: Investorideas.com stock directories are part of the
membership program on the site, accessed either by login and password or
available in PDF format.  The directories include stocks trading on the
TSX, OTC, NASDAQ, NYSE and other recognized global stock exchanges, giving
retail investors a wide variety of stocks to review.

About
Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a
recognized news source publishing third party news and press releases plus we
create original financial content. Learn about investing in stocks and 
sector trends  from Investorideas.com with our news alerts , articles ,
podcasts and videos  talking
about cannabis,  crypto,  technology including  AI and IoT ,
mining ,sports biotech, water, renewable energy and more . Investorideas.com
original branded content includes the daily
Crypto Corner and Podcast, Play by Play sports and stock news column, Investor
Ideas #Potcasts

#Cannabis News and Stocks on the Move podcast and column,  Cleantech and
Climate Change Podcast and  the Stock Guru daily podcast on Support and
Resistance Trading.

Disclaimer/Disclosure: Investorideas.com is a
digital publisher of third party sourced news, articles and equity research as
well as creates original content, including video, interviews and articles.
Original content created by investorideas is protected by copyright laws other
than syndication rights. Our site does not make recommendations for purchases or
sale of stocks, services or products. Nothing on our sites should be construed
as an offer or solicitation to buy or sell products or securities. All
investment involves risk and possible loss of investment. This site is
currently compensated for news publication and distribution, social media and
marketing, content creation and more. Contact each company directly regarding
content and press release questions. Disclosure is posted for each compensated
news release, content published /created if required but otherwise the news was
not compensated for and was published for the sole interest of our readers and
followers. More disclaimer and disclosure info:
http://www.investorideas.com/About/Disclaimer.asp.
Additional info regarding
BC Residents and global Investors: Effective September 15 2008 - all BC
investors should review all OTC and Pink sheet listed companies for adherence
in new disclosure filings and filing appropriate documents with Sedar. Read for
more info:
http://www.bcsc.bc.ca/release.aspx?id=6894.  Global investors must adhere to
regulations of each country.

Please read
Investorideas.com privacy policy:
http://www.investorideas.com/About/Private_Policy.asp

Learn more about our news, PR and social media
services at Investorideas.com


To sponsor one of our
podcasts or columns or be a guest call us today!

Contact
Investorideas.com
800-665-0411







Friday, June 8, 2018

Investorideas.com - Investor Ideas Adds New Stocks in #Biotech, #Solar, #Cannabis and #Blockchain; $IZO.C, $ATIS, $PPL, $ICAN.C, $VRCP

Investorideas.com - Investor Ideas Adds New Stocks in #Biotech, #Solar, #Cannabis and #Blockchain; $IZO.C, $ATIS, $PPL, $ICAN.C, $VRCP





Point Roberts, WA, Delta BC – June 8, 2018 –
Investorideas.com, a global news source and leading investor resource covering
actively traded sectors announces this week’s additions to its
global stock directories in biotech, solar, cannabis and blockchain

Investorideas.com tracks companies in high-profile
trading sectors and makes ongoing additions to its stock directories for its
members.  Free previews of all
directories are available to the public with full login access only accessible
to members.





The newest biotech companies are involved in breast
cancer diagnostics and healthcare business centers respectively with Attis
Industries Inc. (NasdaqCM: ATIS) crossing over onto our water stock list with
their recent investment in Noveda Technologies Inc.

Friday, March 16, 2018

Investor Ideas Adds New Stocks in #Biotech, #Tech, #Mining and #Cannabis; (NasdaqCM: $BTAI), (NYSE: $MDT), (NASDAQGM: $FSCT), (CSE: $PRIM.V), (CSE: $CNNX.C)


Investor Ideas Adds New Stocks in #Biotech, #Tech, #Mining and #Cannabis; (NasdaqCM: $BTAI), (NYSE: $MDT), (NASDAQGM: $FSCT), (CSE: $PRIM.V), (CSE: $CNNX.C)


Point Roberts, WA, Delta BC – March 16, 2018 – Investorideas.com, a global news source and leading investor resource covering actively traded sectors announces this week’s additions to its global stock directories in biotech, tech, mining and cannabis.

Investorideas.com tracks companies in high-profile trading sectors and makes ongoing additions to its stock directories for its members.  Free previews of all directories are available to the public with full login access only accessible to members.


The newest biotech companies include the Nasdaq IPO, BioXcel THERAPEUTICS, INC. (NasdaqCM:BTAI), a clinical stage biopharmaceutical company using AI in neuroscience and immuno-oncology, as well as two NYSE-Listed medical technology companies.

The latest tech companies are both Nasdaq listed and are involved in cyber/network security and the Artificial intelligence (AI)/fintech sectors.

The new mining and cannabis companies are both CSE-Listed IPOs.

New Biotech Companies Added:
BioXcel THERAPEUTICS, INC. ( NasdaqCM:BTAI) is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. The company`s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. The company`s two most advanced clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer.

Medtronic plc (NYSE:MDT) headquartered in Dublin, Ireland, is among the world's largest medical technology, services and solutions companies - alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 84,000 people worldwide, serving physicians, hospitals and patients in approximately 160 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

Smith & Nephew (LSE:SN.L, NYSE:SNN) is a global medical technology business dedicated to helping healthcare professionals improve people's lives. With leadership positions in Orthopaedic Reconstruction, Advanced Wound Management, Sports Medicine and Trauma & Extremities, Smith & Nephew has more than 15,000 employees and a presence in more than 100 countries.

New Tech Companies Added:
ForeScout Technologies, Inc. (NASDAQGM:FSCT) helps make the invisible visible. Our company provides Global 2000 enterprises and government agencies with agentless visibility and control of traditional and IoT devices the instant they connect to the network. Our technology integrates with disparate security tools to help organizations accelerate incident response, break down silos, automate workflows and optimize existing investments.

Virtusa Corporation (NasdaqGS: VRTU) is a global provider of information technology (IT) consulting and outsourcing services that accelerate business outcomes for Global 2000 companies and leading software vendors in banking and financial services, insurance, healthcare, telecommunications, technology, and media & entertainment. Through its Data & Analytics practice, Virtusa provides services and solutions across the entire data spectrum – transforming raw data into actionable insights. Virtusa’s Big Data Competency Center offers consulting services for roadmap development, tool evaluations, solution architecture and design and end-to-end implementation services using big data ecosystems such as Hadoop, NO SQL and graph databases. The company’s centers of excellence utilize business intelligence (BI) and artificial intelligence (AI) to offer comprehensive services that span from traditional BI to more complex and advanced analytical solutions, including social analytics, web data analytics, predictive analytics and model implementation. Virtusa has created a robust platform to provide end-to-end solutions and services in banking and financial services, strengthening its positioning as a top, global FinTech services provider. Virtusa Corporation is headquartered in Massachusetts and has 50 offices across North America, Europe and Asia.

New Mining Companies Added:
Primary Cobalt Corp. (CSE:PRIM) is a Vancouver, B.C based company with an option to acquire five mineral claims covering an area of approximately 7,327.32 hectares located in the Hazelton area of B.C. The Company’s planned 2018 exploration program of $115,610 is further exploration for cobalt, gold and silver.

New Cannabis Companies Added:
Cannex Capital Holdings Inc. (CSE:CNNX) through its wholly-owned subsidiaries, provides a range of comprehensive and flexible growth options for licensed cannabis cultivators, processors and/or dispensaries domestically and internationally, including providing turn-key real estate with operational infrastructure as well as long term advisory and consulting services. Cannex has acquired BrightLeaf Development LLC (“BLD”), a limited liability company that, through subsidiaries, holds real estate assets, property leases, brands and intellectual property, and material supply agreements with Superior Gardens LLC (d/b/a Northwest Cannabis Solutions), Washington State’s and the Pacific Northwest’s largest full-line cannabis producer/processor, and also 7Point Holdings LLC, another Washington State licensed cannabis producer/processor. Cannex is managed by a team of experienced industry and capital markets experts who are committed to aggressive, cost-effective growth and is based in Vancouver, British Columbia. Cannex is currently undertaking an expansion initiative to support the acquisition and development of additional assets, in Canada and internationally, that is expected to serve and support the growing legal medical and recreational cannabis markets. Cannex is also exploring several international opportunities in countries that have legal and strongly regulated medical and recreational cannabis sectors.

The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

About Investorideas.com - News that Inspires Big Ideas
www.Investorideas.com  is a meeting place for global investors, featuring news, stock directories, video, podcasts, company profiles, interviews and more in leading sectors. Sectors we cover include tech (AI, drones, internet of things) , payments,  crypto and blockchain, biotech, mining, energy, renewable energy, water , marijuana and hemp stocks, food and beverage, defense and security (biometrics/cyber) ,Latin America, sports, entertainment, luxury brands and gaming.

The Investorideas.com content portfolio goes beyond the www.investorideas.com site to include 14 blogs on Blogger.com, 7 Artificial Intelligence (AI) websites on the Grid and the Waternewswire.com, all featuring Investorideas.com news and content.

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Investor Ideas Stock Directories for global investors:
From water stocks to gold and mining stocks, renewable energy, nanotech, defense, technology, biotech and more – use our stock directories and access them online 24/7 with login as a member to find your next big idea!

Services for Publicly traded companies: http://www.investorideas.com/Investors/Services.asp

Investorideas.com is also a CSE service provider: http://thecse.com/en/services/services-for-listed-companies

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894.  Global investors must adhere to regulations of each country.

Contact Investorideas.com
800-665-0411